patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_796060 | REC_0011601 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 12.9 | 67 | male | 1 | 9 | 6 | 8 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:59.766912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572377 | REC_0011602 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 29 | 12.7 | 69 | female | 0 | 14 | 4.9 | 0 | sotorasib 960 mg daily | 41.2 | false | MSS | 2026-03-15T05:35:59.767144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753526 | REC_0011603 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 3.3 | 63 | female | 0 | 18 | 5.2 | 9 | sotorasib 960 mg daily | 12 | true | MSS | 2026-03-15T05:35:59.767375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443883 | REC_0011604 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.4 | 66 | female | 1 | 11 | 4.5 | 2 | pembrolizumab 200 mg q3w | 17.8 | false | MSS | 2026-03-15T05:35:59.767602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180844 | REC_0011605 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 11.8 | 54 | male | 0 | 12 | 7 | 3 | alectinib 600 mg BID | 16.4 | true | MSS | 2026-03-15T05:35:59.767841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393006 | REC_0011606 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 7.9 | 60 | female | 1 | 23 | 5.8 | 6 | osimertinib 80 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:59.768102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270828 | REC_0011607 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.5 | 59 | male | 1 | 41 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:59.768340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701953 | REC_0011608 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.6 | 72 | female | 0 | 23 | 5.7 | 4 | alectinib 600 mg BID | 14 | true | MSI-H | 2026-03-15T05:35:59.768577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590810 | REC_0011609 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.8 | 68 | female | 1 | 26 | 5.4 | 6 | sotorasib 960 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:59.768805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548415 | REC_0011610 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 10.7 | 72 | female | 2 | 19 | 6.2 | 1 | alectinib 600 mg BID | 13.9 | true | MSI-H | 2026-03-15T05:35:59.769097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662680 | REC_0011611 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 10.1 | 73 | female | 1 | 18 | 5 | 2 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:59.769332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876063 | REC_0011612 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 13.5 | 87 | female | 2 | 12 | 4.5 | 3 | entrectinib 600 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:35:59.769566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158355 | REC_0011613 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 18 | 6.9 | 61 | male | 0 | 24 | 3.9 | 1 | pembrolizumab 200 mg q3w | 20.5 | false | MSS | 2026-03-15T05:35:59.769802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975511 | REC_0011614 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 35 | 12.1 | 54 | female | 0 | 22 | 5.8 | 1 | entrectinib 600 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:59.770033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879530 | REC_0011615 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.8 | 63 | female | 0 | 44 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 15 | true | MSS | 2026-03-15T05:35:59.770266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538884 | REC_0011616 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 19 | 58 | male | 0 | 31 | 4.2 | 9 | osimertinib 80 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:59.770499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564922 | REC_0011617 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 8.7 | 77 | female | 1 | 20 | 6 | 1 | entrectinib 600 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:59.770728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541363 | REC_0011618 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.7 | 70 | female | 1 | 22 | 4.3 | 3 | osimertinib 80 mg daily | 6.4 | true | MSS | 2026-03-15T05:35:59.770958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427825 | REC_0011619 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 10 | 57 | female | 1 | 19 | 3.9 | 5 | entrectinib 600 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:59.771194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508961 | REC_0011620 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 16.8 | 62 | female | 0 | 15 | 4.5 | 4 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:59.771426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401903 | REC_0011621 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.6 | 73 | female | 0 | 17 | 7 | 3 | entrectinib 600 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:59.771657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171310 | REC_0011622 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 14.3 | 57 | male | 1 | 4 | 6.1 | 6 | entrectinib 600 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:35:59.771891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190024 | REC_0011623 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 9.3 | 61 | female | 0 | 15 | 6.1 | 5 | alectinib 600 mg BID | 14.4 | false | MSS | 2026-03-15T05:35:59.772204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881243 | REC_0011624 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 9.6 | 68 | female | 1 | 14 | 4.8 | 3 | alectinib 600 mg BID | 19.5 | false | MSS | 2026-03-15T05:35:59.772439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_632685 | REC_0011625 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.3 | 69 | female | 1 | 14 | 5.5 | 6 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:59.772675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958906 | REC_0011626 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 16.1 | 52 | male | 0 | 14 | 4.7 | 6 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:35:59.772910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423761 | REC_0011627 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.4 | 65 | male | 1 | 10 | 7 | 7 | sotorasib 960 mg daily | 7.1 | true | MSS | 2026-03-15T05:35:59.773141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390620 | REC_0011628 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 5.9 | 79 | female | 2 | 21 | 6 | 3 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.773372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514181 | REC_0011629 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 7.1 | 73 | male | 1 | 11 | 6.7 | 6 | alectinib 600 mg BID | 13.9 | true | MSS | 2026-03-15T05:35:59.773602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361680 | REC_0011630 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 8.6 | 69 | male | 1 | 20 | 3.3 | 8 | osimertinib 80 mg daily | 8.8 | true | MSS | 2026-03-15T05:35:59.773835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760450 | REC_0011631 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 5.6 | 71 | female | 2 | 27 | 6 | 8 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.774064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464561 | REC_0011632 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 19.7 | 69 | male | 0 | 14 | 5.3 | 2 | alectinib 600 mg BID | 13.7 | false | MSS | 2026-03-15T05:35:59.774297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546924 | REC_0011633 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 14.2 | 72 | male | 2 | 12 | 6.6 | 2 | entrectinib 600 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:59.774531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664545 | REC_0011634 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.1 | 62 | female | 1 | 44 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:35:59.774762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710925 | REC_0011635 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 12.9 | 64 | male | 0 | 9 | 2.9 | 6 | pembrolizumab 200 mg q3w | 7.7 | false | MSI-H | 2026-03-15T05:35:59.774995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947719 | REC_0011636 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.5 | 71 | female | 1 | 68 | 8.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:35:59.775266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941982 | REC_0011637 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.6 | 75 | female | 1 | 12 | 5.4 | 5 | sotorasib 960 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:59.775503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674269 | REC_0011638 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.8 | 54 | female | 0 | 14 | 6.7 | 7 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:59.775740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545583 | REC_0011639 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 2.5 | 84 | male | 1 | 25 | 6.8 | 2 | sotorasib 960 mg daily | 21.7 | true | MSS | 2026-03-15T05:35:59.775971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558491 | REC_0011640 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 14.8 | 61 | male | 0 | 16 | 7.9 | 2 | entrectinib 600 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:59.776366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407139 | REC_0011641 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13.2 | 85 | male | 2 | 13 | 5.9 | 6 | entrectinib 600 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:59.776613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319904 | REC_0011642 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.9 | 76 | female | 2 | 12 | 6.2 | 4 | sotorasib 960 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:59.776849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968737 | REC_0011643 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 16.1 | 82 | female | 2 | 3 | 6.8 | 8 | alectinib 600 mg BID | 6.6 | true | MSS | 2026-03-15T05:35:59.777085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262111 | REC_0011644 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.6 | 68 | female | 0 | 39 | 4.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.5 | true | MSS | 2026-03-15T05:35:59.777312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142858 | REC_0011645 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 13.9 | 58 | female | 1 | 17 | 7.2 | 2 | entrectinib 600 mg daily | 27.5 | true | MSS | 2026-03-15T05:35:59.777548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355615 | REC_0011646 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.9 | 80 | female | 1 | 21 | 4.5 | 7 | alectinib 600 mg BID | 11.8 | false | MSS | 2026-03-15T05:35:59.777779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249800 | REC_0011647 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 7.8 | 59 | male | 0 | 25 | 6.5 | 4 | osimertinib 80 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:59.778012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532638 | REC_0011648 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 10.3 | 69 | male | 0 | 13 | 5.3 | 1 | osimertinib 80 mg daily | 21.1 | true | MSI-H | 2026-03-15T05:35:59.778245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571928 | REC_0011649 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 15.8 | 54 | female | 0 | 14 | 5.6 | 4 | entrectinib 600 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:59.778526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126866 | REC_0011650 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 12.9 | 63 | male | 0 | 15 | 5.7 | 8 | alectinib 600 mg BID | 8 | false | MSS | 2026-03-15T05:35:59.778763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606921 | REC_0011651 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 8.7 | 69 | female | 0 | 15 | 5.3 | 7 | osimertinib 80 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:59.778991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489392 | REC_0011652 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.3 | 58 | female | 0 | 11 | 6.8 | 8 | sotorasib 960 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:59.779225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159248 | REC_0011653 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5 | 64 | female | 1 | 23 | 6.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.779456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369753 | REC_0011654 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.9 | 56 | female | 1 | 24 | 4.2 | 4 | alectinib 600 mg BID | 11.2 | true | MSI-H | 2026-03-15T05:35:59.779692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403974 | REC_0011655 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.6 | 69 | male | 1 | 10 | 4.2 | 5 | osimertinib 80 mg daily | 17.2 | false | MSI-H | 2026-03-15T05:35:59.779928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605026 | REC_0011656 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 16 | 56 | male | 1 | 10 | 3.4 | 5 | pembrolizumab 200 mg q3w | 8.3 | true | MSS | 2026-03-15T05:35:59.780190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466975 | REC_0011657 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.3 | 79 | female | 0 | 28 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 7 | true | MSS | 2026-03-15T05:35:59.780421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623395 | REC_0011658 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 20 | 6.8 | 56 | female | 0 | 62 | 3.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 21 | true | MSS | 2026-03-15T05:35:59.780735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381002 | REC_0011659 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 15.1 | 64 | female | 0 | 13 | 2.6 | 5 | osimertinib 80 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:59.780977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308096 | REC_0011660 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 15.2 | 56 | female | 0 | 10 | 5.5 | 1 | osimertinib 80 mg daily | 17.9 | false | MSS | 2026-03-15T05:35:59.781216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506624 | REC_0011661 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 8.5 | 48 | male | 0 | 22 | 6 | 1 | sotorasib 960 mg daily | 24.6 | false | MSS | 2026-03-15T05:35:59.781447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895190 | REC_0011662 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 7 | 54 | male | 0 | 16 | 3.6 | 7 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:59.781723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501631 | REC_0011663 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 8.9 | 56 | male | 1 | 5 | 8.7 | 6 | osimertinib 80 mg daily | 11 | true | MSS | 2026-03-15T05:35:59.781958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739111 | REC_0011664 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 8.5 | 58 | male | 1 | 23 | 5.1 | 5 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:59.782188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221313 | REC_0011665 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 5.8 | 61 | male | 0 | 6 | 5 | 2 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:59.782420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254143 | REC_0011666 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 16.2 | 77 | female | 2 | 23 | 4.5 | 6 | osimertinib 80 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:59.782649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315844 | REC_0011667 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.7 | 77 | female | 2 | 14 | 4.2 | 5 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:59.782876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508758 | REC_0011668 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 18.1 | 67 | female | 0 | 19 | 5.1 | 6 | osimertinib 80 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:59.783106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376058 | REC_0011669 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 12 | 63 | female | 0 | 21 | 6.5 | 2 | sotorasib 960 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:59.783343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736050 | REC_0011670 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.4 | 81 | female | 2 | 13 | 4.2 | 6 | entrectinib 600 mg daily | 17 | true | MSI-H | 2026-03-15T05:35:59.783578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691339 | REC_0011671 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 15 | 65 | female | 0 | 15 | 7.3 | 5 | alectinib 600 mg BID | 7.1 | false | MSS | 2026-03-15T05:35:59.783814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899121 | REC_0011672 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.7 | 69 | male | 0 | 26 | 4.3 | 4 | sotorasib 960 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:59.784044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667941 | REC_0011673 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.2 | 75 | female | 1 | 10 | 3.3 | 1 | pembrolizumab 200 mg q3w | 17.1 | false | MSS | 2026-03-15T05:35:59.784302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565600 | REC_0011674 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 12.4 | 64 | female | 1 | 6 | 2 | 1 | sotorasib 960 mg daily | 19.3 | false | MSI-H | 2026-03-15T05:35:59.784541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150093 | REC_0011675 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.5 | 65 | male | 1 | 9 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 13 | true | MSS | 2026-03-15T05:35:59.784817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788559 | REC_0011676 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 16.1 | 66 | female | 0 | 15 | 7 | 0 | osimertinib 80 mg daily | 45.4 | false | MSI-H | 2026-03-15T05:35:59.785054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927532 | REC_0011677 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.6 | 71 | male | 1 | 15 | 6.3 | 4 | sotorasib 960 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:35:59.785292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571539 | REC_0011678 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 4.1 | 64 | male | 0 | 43 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 32.9 | true | MSS | 2026-03-15T05:35:59.785538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633607 | REC_0011679 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.4 | 79 | female | 2 | 9 | 4.4 | 6 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:59.785800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473110 | REC_0011680 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 5.9 | 76 | female | 1 | 42 | 5.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.5 | false | MSS | 2026-03-15T05:35:59.786041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586599 | REC_0011681 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 9 | 73 | female | 1 | 37 | 3.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.5 | true | MSS | 2026-03-15T05:35:59.786281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520424 | REC_0011682 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.4 | 58 | male | 0 | 20 | 5.1 | 5 | sotorasib 960 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:59.786539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899882 | REC_0011683 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.9 | 79 | female | 2 | 19 | 7.5 | 5 | osimertinib 80 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:59.786783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672719 | REC_0011684 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 37 | 10.4 | 74 | female | 1 | 12 | 5.8 | 5 | sotorasib 960 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:35:59.787026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264202 | REC_0011685 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 11.4 | 84 | male | 0 | 15 | 6.2 | 7 | pembrolizumab 200 mg q3w | 5.1 | true | MSI-H | 2026-03-15T05:35:59.787277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132942 | REC_0011686 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 6.9 | 56 | male | 1 | 7 | 4.8 | 4 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:59.787543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230069 | REC_0011687 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 13.2 | 59 | female | 0 | 20 | 6.8 | 5 | osimertinib 80 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:35:59.787793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379430 | REC_0011688 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 12.4 | 62 | male | 0 | 13 | 4.5 | 0 | osimertinib 80 mg daily | 21.5 | true | MSI-H | 2026-03-15T05:35:59.788236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141543 | REC_0011689 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.6 | 66 | female | 1 | 29 | 5.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:35:59.788503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127006 | REC_0011690 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 8.3 | 73 | female | 1 | 14 | 6.1 | 2 | entrectinib 600 mg daily | 22 | false | MSS | 2026-03-15T05:35:59.788739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208203 | REC_0011691 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 7.4 | 58 | male | 1 | 47 | 3.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 5 | true | MSS | 2026-03-15T05:35:59.788977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244320 | REC_0011692 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 7.6 | 66 | female | 1 | 12 | 5.9 | 1 | entrectinib 600 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:59.789216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126198 | REC_0011693 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11.3 | 63 | male | 0 | 13 | 6.4 | 1 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.789468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223758 | REC_0011694 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.4 | 57 | female | 1 | 21 | 6.3 | 1 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:59.789704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612787 | REC_0011695 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 9.5 | 72 | male | 2 | 18 | 3.1 | 2 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:59.789940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676792 | REC_0011696 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.9 | 72 | female | 1 | 15 | 6.5 | 5 | osimertinib 80 mg daily | 4.6 | false | MSI-H | 2026-03-15T05:35:59.790175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116571 | REC_0011697 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 14.1 | 62 | female | 1 | 8 | 5.4 | 4 | sotorasib 960 mg daily | 4.2 | true | MSS | 2026-03-15T05:35:59.790408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316969 | REC_0011698 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.4 | 47 | female | 0 | 14 | 7 | 5 | osimertinib 80 mg daily | 6.8 | true | MSS | 2026-03-15T05:35:59.790644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213896 | REC_0011699 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7 | 75 | female | 1 | 43 | 7 | 2 | carboplatin + paclitaxel + pembrolizumab | 18 | false | MSS | 2026-03-15T05:35:59.790875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854306 | REC_0011700 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 10.8 | 73 | female | 3 | 9 | 5.7 | 2 | osimertinib 80 mg daily | 27.3 | true | MSI-H | 2026-03-15T05:35:59.791104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.